Extended treatment of Cushing's disease with pasireotide: Results from a 2-year, Phase II study

M. Boscaro, J. Bertherat, J. Findling, M. Fleseriu, A. B. Atkinson, S. Petersenn, J. Schopohl, P. Snyder, G. Hughes, A. Trovato, K. Hu, M. Maldonado, B. M.K. Biller

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

In a previous 15-day, Phase II study of patients with de novo or persistent/recurrent Cushing's disease (core study), treatment with pasireotide 600 μg sc bid reduced urinary free cortisol (UFC) levels in 76 % of patients and normalized UFC in 17 %. The objective of this study was to evaluate the efficacy and safety of extended treatment with pasireotide. This was a planned, open-ended, single-arm, multicenter extension study (primary endpoint: 6 months). Patients aged ≥18 years with Cushing's disease who completed the core study could enter the extension if they achieved UFC normalization at core study end and/or obtained significant clinical benefit. Of the 38 patients who completed the core study, 19 entered the extension and 18 were included in the efficacy analyses (three responders, 11 reducers, four non-reducers in the core study). At data cut-off, median treatment duration in the extension was 9.7 months (range: 2 months to 4.8 years). At extension month 6, 56 % of the 18 patients had lower UFC than at core baseline and 22 % had normalized UFC. Of the four patients who remained on study drug at month 24, one had normalized UFC. Reductions in serum cortisol, plasma adrenocorticotropic hormone, body weight and diastolic blood pressure were observed. The most common adverse events were mild-to-moderate gastrointestinal disorders and hyperglycemia. Pasireotide offers a tumor-directed medical therapy that may be effective for the extended treatment of some patients with Cushing's disease.

Original languageEnglish (US)
Pages (from-to)320-326
Number of pages7
JournalPituitary
Volume17
Issue number4
DOIs
StatePublished - Aug 2014

Keywords

  • Clinical trial
  • Cushing's disease
  • Pasireotide
  • SOM230
  • Somatostatin analogue

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Extended treatment of Cushing's disease with pasireotide: Results from a 2-year, Phase II study'. Together they form a unique fingerprint.

  • Cite this

    Boscaro, M., Bertherat, J., Findling, J., Fleseriu, M., Atkinson, A. B., Petersenn, S., Schopohl, J., Snyder, P., Hughes, G., Trovato, A., Hu, K., Maldonado, M., & Biller, B. M. K. (2014). Extended treatment of Cushing's disease with pasireotide: Results from a 2-year, Phase II study. Pituitary, 17(4), 320-326. https://doi.org/10.1007/s11102-013-0503-3